BRIEF-Schrödinger Reports New Preclinical Data Supporting Advancement Of Its Wee1 Inhibitor Program
* SCHRÖDINGER REPORTS NEW PRECLINICAL DATA SUPPORTING ADVANCEMENT OF ITS WEE1 INHIBITOR PROGRAM AT AMERICAN ASSOCIATION OF CANCER RESEARCH 2022 ANNUAL MEETING
* SCHRODINGER INC (SDGR) - HIGHLY SELECTIVE AND STRUCTURALLY-DISTINCT WEE1 INHIBITORS DEMONSTRATE STRONG ANTI-TUMOR ACTIVITY IN TUMOR MODELS
* SCHRODINGER INC (SDGR) - ON TRACK TO SELECT A WEE1 DEVELOPMENT CANDIDATE IN 2022 Source text for Eikon: Further company coverage: